Skip to main content
. 2022 Feb 8;13(2):122. doi: 10.1038/s41419-022-04594-2

Fig. 3. sEVs derived from syntenin-1-knockdown cancer cells abolished the stimulatory effects of sEVs on the migration of cancer and endothelial cells, and endothelial cell tube fromation.

Fig. 3

A sEVs purified from NCI-H226 cells were labelled with PKH26, and A549 cells and HUVECs were were incubated with PKH26-labelled sEVs for 12 h. Confocal images show uptake of sEVs by target cells. Cell nuclei were stained with DAPI. Scale bar, 20 μm. B–F sEVs were purified from the indicated human lung cancer cell lines that were transfected with control (Con) siRNA or syntenin-1 (Syn) siRNA. Transwell migration assays (n = 3) were performed to assess the migratory ability of A549 cells with or without the purified sEVs (109 particles/ml). G HUVECs were treated with sEVs (109 particles/ml) derived from NCI-H226 cells that were transfected with control (Con) siRNA or syntenin-1 (Syn) siRNA. Transwell migration assays (n = 4) were performed to assess the migratory ability of HUVECs with or without VEGF (10 ng/ml). H Tube formation assays (n = 3) for HUVECs were performed in the presence of sEVs (109 particles/ml) derived from NCI-H226 cells that were transfected with control (Con) siRNA or syntenin-1 (Syn) siRNA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.